Agonists of gonadotropin-releasing hormone: their role in the complex therapy of hyperplastic processes in reproductive organs

Lyudmila Vladimirona Tkachenko; Nataliya Ivanovna Sviridova

doi:10.17816/JOWD6326-11

Journal of obstetrics and women's diseases ›› 2014, Vol. 63 ›› Issue (2) : 6 -11. DOI: 10.17816/JOWD6326-11

Articles

research-article

Agonists of gonadotropin-releasing hormone: their role in the complex therapy of hyperplastic processes in reproductive organs

Author information +

History +

PDF

Abstract

The aim of this study was to evaluate the efficacy of an agonist of gonadotropin-releasing hormone Buserilin in the treatment of patients with endometriosis in combination with endometrial hyperplasia. We conducted a clinical and laboratory examination and treatment of 108 patients aged 41 to 52 years old suffering from endometriosis varying degrees of prevalence in conjunction with endometrial hyperplasia. The results obtained suggest a scientifically sound complex treatment of patients with endometriosis on the background of endometrial hyperplasia with a GnRH agonist Buserilin-depo in the postoperative period, followed by the appointment of progestogens or combiened oral contraceptives as a long-term program management of patients to prevent relapse and re-operative treatment.

Keywords

perimenopause / endometrial hyperplasia / endometriosis / hormonal therapy

Cite this article

Download citation ▾

Lyudmila Vladimirona Tkachenko, Nataliya Ivanovna Sviridova. Agonists of gonadotropin-releasing hormone: their role in the complex therapy of hyperplastic processes in reproductive organs. Journal of obstetrics and women's diseases, 2014, 63(2): 6-11 DOI:10.17816/JOWD6326-11

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Адамян Л. В., Кулаков В. И., Андреева Е. Н. Эндометриозы. Руководство для врачей. Изд. 2-е. М.: Медицина, 2006; 411.

[2]	Адамян Л. В., Осипова А. А., Сонова М. М. Эволюция гормональной терапии эндометриоза. Пробл. репрод., 2006; 5: 11-16.

[3]	Ашрафян Л. А., Киселев В. И. Опухоли репродуктивных органов (этиология и патогенез). М., 2008.

[4]	Киселев В. И., Сидорова И. С., Унанян А. П., Муйжнек Е. Л. Гиперпластические процессы органов женской репродуктивной системы: теория и практика. М.: Медпрактика-М, 2011; 468 с.

[5]	Кузнецова И. В. Эндометриоз. М., 2010.- С. 45

[6]	Макаров И. О., Овсянникова Т. В., Шешукова Н. А., Федотова А. С. Онкологические аспекты гиперпластических процессов в эндометрии. Российский Вестник акушера-гинеколога. 2011; 1: 13-15.

[7]	Чернуха Г. Е. Гиперплазия эндометрия: перспективы развития проблемы. Акушерство и гинекология. 2009; 4: 11-15.

[8]	Шешукова Н. А., Макаров И. О., Фомина М. Н. Гиперпластические процессы эндометрия: этиопатогенез, клиника, диагностика, лечение. Акушерство и гинекология. 2011; 4: 16-21.

[9]	Эндометриоз: диагностика, лечение и реабилитация. В кн. Адамян Л. В. ред. Федеральные клинические рекомендации по ведению больных. М.; 2013.

[10]	ACOG Education Pamphlet AP013. Washington, DC. Am. Coll. Obstet. 2008; ISSN 1074-8601.

[11]	International collaborations in cancer control and the Third international Cancer Control Congress. Timori. 2009; 95: 579-596.

[12]	Varma R., Soneja H., Bhatia K. et al. The effectiveness of a levonorgestrel-releasing intrauterinesystem (LNG-IUS) in the treatment of endometrial hyperplasia-along-term follow-up study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008; 139: 169-175.